Protease inhibitor trials moving to next phase.
D000998:Antiviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic / Q000379:methods*; D004359:Drug Therapy, Combination; D006678:HIV / Q000502:physiology; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use; D019888:Nelfinavir; D011804:Quinolines / Q000627:therapeutic use; D019438:Ritonavir; D019258:Saquinavir; D018119:Stavudine / Q000008:administration & dosage; D013844:Thiazoles / Q000627:therapeutic use; D014633:Valine / Q000627:therapeutic use; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D011804:Quinolines; D013844:Thiazoles; D018119:Stavudine; D014633:Valine; D019888:Nelfinavir; D019258:Saquinavir; D019438:Ritonavir